Table 2 Characteristics and supportive therapies used with ICU-AAV patients

Reasons for ICU admission, n (%)

 Respiratory failure

44 (45.4)

  And renal failure

23 (23.7)

  And neurological failure

1 (1.0)

 Acute renal failure

17 (17.5)

  And neurological failure

4 (4.1)

 Neurological failure

4 (4.1)

 Heart failure

3 (3.1)

 Hemorrhagic shock

1 (1.0)

SOFA (at admission)

6 (4.0–9.0)

SAPS II

39.0 (31.0–51.0)

Respiratory assistance, n (%)

 Mechanical ventilation

  Invasive or/and noninvasive

66 (68.0)

    Within 48 h of admission

58 (59.8)

  Noninvasive ventilation only

19 (19.6)

  Invasive ventilation only

36 (37.1)

  Noninvasive and invasive ventilation

11 (11.3)

 Length of respiratory assistance (days)

10.0 (5.5–18.5)

 PaO₂/FiO₂

92.0 (58.8–182.0)

Kidney involvement

 Serum creatinine at admission, (μmol/L)

256.5 (115.3–527.8)

 Maximum serum creatinine in ICU, (μmol/L)

348.0 (160.0–673.0)

 AKIN score ≥1, n (%)

89 (91.8)

 Renal replacement therapy, n (%)

55 (56.7)

  Within 48 h of admission

34 (35.1)

Hemodynamic assistance

 Vasopressive amines, n (%)

26 (26.8)

  Within 48 h

25 (25.8)

 Length of treatment (days)

6.0 (3–11.5)

Infectious events

 Early/late*

29/10

  Lung infection, n (%)

29 (74.4)**

  Other sites, n (%)

10 (25.6)**

  Patients with pathogen identified, n (%)

32 (82.1)**